Gts Securities LLC Biogen Inc. Call Options Transaction History

Gts Securities LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $1.14 Million - $1.42 Million	-6,000 Reduced 38.22%	9,700 $2.25 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $7.02 Million - $8.86 Million	-33,100 Reduced 67.83%	15,700 $3.39 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $222,590 - $267,940	1,000 Added 2.09%	48,800 $12.6 Million
Q3 2023 Nov 15, 2023	BUY	$253.3 - $285.89 $12.1 Million - $13.7 Million	47,800 New	47,800 $12.3 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.